【レポートの概要（一部）】
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by Application
08. Global Antibacterial Drugs Market
08.1 Introduction
08.2 Market Size and Forecast
08.3 Market Segmentation by Chemical Class
08.4 Market Segmentation by Drug Origin
09. Global Antifungal Drugs Market
09.1 Introduction
09.2 Market Size and Forecast
09.3 Market Segmentation by Chemical Class
09.4 Market Segmentation by Geography
09.4.1 Antifungal Drugs Market in the US
09.4.2 Antifungal Drugs Market in Europe
10. Global Antiviral Drugs Market
10.1 Introduction
10.2 Market Size and Forecast
10.3 Market Segmentation by Disease
10.4 Global Hepatitis C Drugs Market
10.4.1 Market Size and Forecast
10.4.2 Geographical Segmentation
10.5 Global Hepatitis B Drugs Market
10.5.1 Market Size and Forecast
10.6 Global HIV Drugs Market
10.6.1 Market Size and Forecast
11. Global Antiparasitic Drugs Market
11.1 Market Size and Forecast
12. Geographical Segmentation
13. Buying Criteria
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
20. Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2013
20.2.1 Gilead Sciences
20.2.2 GlaxoSmithKline
20.2.3 Pfizer
20.2.4 F. Hoffmann-La Roche
20.2.5 Johnson & Johnson
20.2.6 Merck
20.3 Other Prominent Vendors
21. Key Vendor Analysis
21.1 F. Hoffmann La Roche
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Segmentation by Revenue 2013
21.1.4 Business Segmentation by Revenue 2012 and 2013
21.1.5 Geographical Segmentation by Revenue 2013
21.1.6 Business Strategy
21.1.7 Recent Developments
21.1.8 SWOT Analysis
21.2 Gilead Sciences
21.2.1 Key Facts
21.2.2 Business Overview
21.2.3 Geographical Segmentation by Revenue 2013
21.2.4 Recent Developments
21.2.5 SWOT Analysis
21.3 GlaxoSmithKline plc
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Business Segmentation
21.3.4 Business Segmentation by Revenue 2012 and 2013
21.3.5 Sales by Geography
21.3.6 Pipeline Products
21.3.7 Business Strategy
21.3.8 Key Information
21.3.9 SWOT Analysis
21.4 Johnson & Johnson
21.4.1 Key Facts
21.4.2 Business Overview
21.4.3 Business Segmentation by Revenue 2013
21.4.4 Business Segmentation by Revenue 2012 and 2013
21.4.5 Geographical Segmentation by Revenue 2013
21.4.6 Business Strategy
21.4.7 Recent Developments
21.4.8 SWOT Analysis
21.5 Merck
21.5.1 Key Facts
21.5.2 Business Overview
21.5.3 Business Segmentation by Revenue 2013
21.5.4 Business Segmentation by Revenue 2012 and 2013
21.5.5 Sales by Geography
21.5.6 Business Strategy
21.5.7 Key Developments
21.5.8 SWOT Analysis
21.6 Pfizer
21.6.1 Key Facts
21.6.2 Business Description
21.6.3 Business Segmentation
21.6.4 Revenue by Business Segmentation
21.6.5 Revenue Comparison 2012 and 2013
21.6.6 Sales by Geography
21.6.7 Business Strategy
21.6.8 Key Developments
21.6.9 SWOT Analysis
22. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Infectious Disease Treatment Market 2013-2018 (US$ million)
Exhibit 3: Global Infectious Disease Treatment Market Segmentation by Application
Exhibit 4: Global Infectious Disease Treatment Market Segmentation by Application 2013
Exhibit 5: Global Infectious Disease Treatment Market Segmentation by Application 2018
Exhibit 6: Global Infectious Disease Treatment Market Segmentation by Application 2013-2018 (US$ million)
Exhibit 7: Global Infectious Disease Treatment Market Segmentation by Application 2013-2018
Exhibit 8: Snapshot of Global Infectious Disease Treatment Market Segments 2013-2018
Exhibit 9: YoY Growth Rate of Global Infectious Disease Treatment Market Segments 2013-2018
Exhibit 10: Global Antibacterial Drugs Market: Key Drivers and Challenges
Exhibit 11: Global Antibacterial Drugs Market 2013-2018 (US$ million)
Exhibit 12: Global Antibacterial Drugs Market Segmentation by Chemical Class
Exhibit 13: Cephalosporin Segmentation by Generation of Drugs
Exhibit 14: Global Antibacterial Drugs Market Revenue Segmentation by Chemical Class 2013
Exhibit 15: Global Antibacterial Drugs Market Segmentation by Chemical Class in Volume 2013
Exhibit 16: Global Antibacterial Drugs Market Segmentation by Drug Origin
Exhibit 17: Global Antifungal Drugs Market: Key Drivers and Challenges
Exhibit 18: Global Antifungal Drugs Market 2013-2018 (US$ million)
Exhibit 19: Global Antifungal Drugs Market Segmentation by Chemical Class
Exhibit 20: Global Antifungal Drugs Market Segmentation by Chemical Class 2013
Exhibit 21: Global Antifungal Drugs Market by Geography Segmentation 2013
Exhibit 22: Antifungal Drugs Market in the US 2013-2018 (US$ million)
Exhibit 23: Antifungal Drugs Market in Europe 2013-2018 (US$ million)
Exhibit 24: Global Antiviral Drugs Market: Key Drivers and Challenges
Exhibit 25: Global Antiviral Drugs Market 2013-2018 (US$ million)
Exhibit 26: Global Antiviral Drugs Market Segmentation by Disease
Exhibit 27: Global Antiviral Drugs Market Segmentation by Disease 2013
Exhibit 28: Global Antiviral Drugs Market Segmentation by Disease 2018
Exhibit 29: Global Hepatitis C Drugs Market 2013-2018 (US$ million)
Exhibit 30: Global Hepatitis C Market by Geographical Segmentation 2013
Exhibit 31: Global Hepatitis B Drugs Market 2013-2018 (US$ million)
Exhibit 32: Global HIV Drugs Market 2013-2018 (US$ million)
Exhibit 33: Global Antiparasitic Drugs Market: Key Drivers and Challenges
Exhibit 34: Global Antiparasitic Drugs Market 2013-2018 (US$ million)
Exhibit 35: Global Infectious Disease Treatment Market by Geographical Segmentation 2013
Exhibit 36: Global Infectious Disease Treatment Market Share Analysis 2013
Exhibit 37: Revenue of Stribild 2012-2013 (US$ million)
Exhibit 38: Revenue of Truvada 2011-2013 (US$ million)
Exhibit 39: Revenue of Emtriva 2011-2013 (US$ million)
Exhibit 40: Revenue of Atripla 2011-2013 (US$ million)
Exhibit 41: Revenue of Complera/Eviplera 2011-2013 (US$ million)
Exhibit 42: Revenue of Viread 2011-2013 (US$ million)
Exhibit 43: Revenue of Hepsera 2011-2013 (US$ million)
Exhibit 44: Revenue of AmBisome 2011-2013 (US$ million)
Exhibit 45: Gilead Sciences: Percentage Share of Key Antiviral Drugs 2013
Exhibit 46: Share of Key Antiviral Drugs in Gilead Sciences’ Revenue 2013
Exhibit 47: Gilead Sciences: Percentage Share of Key Anti-infective Drugs 2011-2013
Exhibit 48: Gilead Sciences: Drug-wise Sales Comparison of Key Anti-infective Drugs 2011-2013
Exhibit 49: Gilead Sciences: Revenue Trend of Key Anti-infective Drugs 2011-2013
Exhibit 50: Gilead Sciences’ Key Anti-infective Drugs 2011-2013
Exhibit 51: Share of GlaxoSmithKline’s Anti-infective Segment 2013
Exhibit 52: GlaxoSmithKline’s Key Antiviral Drugs Portfolio
Exhibit 53: Share of Key Antiviral Drugs in GlaxoSmithKline’s Antiviral Drugs Segment 2013
Exhibit 54: Geography-wise Segmentation of GlaxoSmithKline’s Antiviral Drugs Segment 2013
Exhibit 55: Geography-wise Segmentation of GlaxoSmithKline’s Key Anti-viral Drugs 2013
Exhibit 56: Geography-wise Segmentation of GlaxoSmithKline’s Key Anti-viral Drugs 2013 (US$ million)
Exhibit 57: GlaxoSmithKline’s Key Antibacterial Drugs Portfolio
Exhibit 58: Share of Augmentin in GlaxoSmithKline’s Antibacterial Drugs Segment Revenue 2013
Exhibit 59: Region-wise Segmentation of GlaxoSmithKline’s Antibacterial Drugs 2013 (US$ million)
Exhibit 60: Geography-wise Segmentation of GlaxoSmithKline’s Antibacterial Drugs 2013
Exhibit 61: Geography-wise Segmentation of GlaxoSmithKline’s Antibacterial Drugs Segment 2013
Exhibit 62: GlaxoSmithKline’s Key Anti HIV Drugs Portfolio (ViiV Healthcare)
Exhibit 63: Geography-wise Segmentation of GlaxoSmithKline’s Key Anti HIV Drugs 2013
Exhibit 64: Geography-wise Segmentation of GlaxoSmithKline’s Key Anti HIV Drugs 2013 (US$ million)
Exhibit 65: Geography-wise Segmentation GlaxoSmithKline’s Anti HIV Drugs Segment 2013
Exhibit 66: Pfizer’s Key Anti-infective Drugs Portfolio
Exhibit 67: Pfizer’s Key Anti-infective Drug Sales 2011-2013
Exhibit 68: Share of F. Hoffmann-La Roche’s Key Anti-infective Drugs 2013
Exhibit 69: Geography-wise Segmentation of Pegasys 2013
Exhibit 70: Geography-wise Segmentation of Tamiflu 2013
Exhibit 71: Share of Johnson & Johnson’s Key Anti-infective Drugs 2013
Exhibit 72: Share of Johnson & Johnson’s Anti-infective Drugs 2011-2013
Exhibit 73: Johnson & Johnson’s Anti-infective Drugs Sales 2011-2013 (US$ million)
Exhibit 74: Johnson & Johnson: Drug-wise Sales Comparison of Anti-infective Drugs 2011-2013
Exhibit 75: Merck’s Key Anti-infective Drugs Portfolio
Exhibit 76: Share of Merck’s Key Anti-infective Drugs 2013
Exhibit 77: Share of Merck’s Key Anti-infective Drugs 2011-2013
Exhibit 78: Share of Merck’s Key Anti-infective Drugs 2011-2013 (US$ million)
Exhibit 79: Merck’s Drug-wise Sales Comparison of Key Anti-infective Drugs 2011-2013
Exhibit 80: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
Exhibit 81: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
Exhibit 82: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Pharmaceuticals Division)
Exhibit 83: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Diagnostics Division)
Exhibit 84: Gilead Sciences: Geographical Segmentation by Revenue 2013
Exhibit 85: GlaxoSmithKline plc: Business Segmentation 2013
Exhibit 86: GlaxoSmithKline plc: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 87: GlaxoSmithKline plc: Sales by Geography 2013
Exhibit 88: GlaxoSmithKline plc: Pipeline Products 2013
Exhibit 89: Johnson & Johnson: Business Segmentation by Revenue 2013
Exhibit 90: Johnson & Johnson: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 91: Johnson & Johnson: Geographical Segmentation by Revenue 2013
Exhibit 92: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 93: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 94: Merck & Co. Inc.: Sales by Geography 2013
Exhibit 95: Pfizer Inc.: Business Segmentation
Exhibit 96: Pfizer Inc.: Revenue by Business Segmentation 2013
Exhibit 97: Pfizer Inc.: Revenue by Business Segmentation 2012 and 2013
Exhibit 98: Pfizer Inc.: Revenue by Geography 2013
【レポート販売概要】
■ タイトル：世界の感染症治療薬市場：抗菌薬、抗ウイルス薬、抗真菌薬、抗寄生虫薬■ 英文：Global Infectious Disease Treatment Market 2014-2018
■ 発行日：2014年8月27日
■ 調査会社：Technavio
■ 商品コード：IRTNTR4063
■ 調査対象地域：グローバル
- 2014年戦略提言：Chancroid Diagnostics検査市場The report presents a detailed analysis of the Chancroid diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Chancroid definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals - Comm …
- 塩素アルカリの世界市場2018-2022About this market Freshwater reserves across the globe have been rapidly depleting due to increased water extraction from aquifers. The rate of water extraction from aquifers is higher than the water replenishing rate. The demand for chlorine and caustic soda is high in the wastewater treatment industry. The rising use of water treatment equipment also impacts the market for chlorine. During the f …
- 神経血管ステントの世界市場2017-2021ABSTRACTAbout Neurovascular Stents A neurovascular stent is a small, flexible, tube-like device made of fabric supported by a metal mesh. It is used to treat several conditions in the brain such as stenosis formation in the blood vessels and ischemic stroke, and aneurysm. Neurovascular stents are segmented into two types based on product types such as carotid artery stents and intracranial stents. …
- ロボットカー/無人車の世界市場分析、セグメント予測The global autonomous cars market is expected to reach 138,089 units by 2024, according to a new study by Grand View Research, Inc. The growing acceptance of semi-autonomous technologies, such as Adaptive Cruise Control (ACC), automatic parking, and forward collision avoidance, is anticipated to pave the way for the adoption of driverless automobiles over the next seven years. An upsurge in the de …
- 鼻咽腔癌：グローバル臨床試験レビュー（2014年上半期）Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2014" provides data on the Nasopharyngeal Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Nasopharyngeal Cancer. It includes an overview of the trial numbers and the …
- 世界の対IED防衛市場動向2013-2023：主な開発プロジェクトThis report discusses the various programmes conducted by key players in the market, by dividing them into the main types of Counter IED. The report offers detailed information regarding quantity procured, country/companies supplying the equipment, delivery period and total contract value.
- 移動式クレーンの世界市場2015-2019About mobile cranes Mobile cranes are cable-controlled or hydraulic-powered cranes, mounted on a rubber-tired or crawler carrier. They are designed to lift and transport various types of loads. These cranes can be powered by electric motors or internal combustion engines. The global mobile crane market is one of the fastest growing segments in the material handling equipment market as a result of …
- 微細セルポリウレタンフォームの世界市場：低密度フォーム、高密度フォームThe global microcellular polyurethane foam market was valued at USD 5.06 Billion in 2015, and is projected to reach USD 6.95 Billion by 2021, at a CAGR of 5.5% between 2016 and 2021. The market is projected witness significant growth in the coming years, owing to the rising demand for lightweight materials from various industries, such as automotive, aerospace, and construction. The automotive, bu …
- ハイドロキシアパタイトの世界市場予測（～2023年）：ナノサイズ、マイクロサイズ、マイクロメートル以上“The Hydroxyapatite (HAp) market is projected to grow at a CAGR of 5.9% between 2018 and 2023.” The HAp market is projected to grow from USD 2.22 billion in 2018 to USD 2.97 billion by 2023, at a CAGR of 5.9% between 2018 and 2023. Growing geriatric population, increasing healthcare expenditure, and increasing demand for medical implants are some of the drivers fueling the growth of the HAp market …
- UV（紫外線）安定剤の世界市場：HALS（光安定剤）、UVA（紫外線吸収剤）、消光剤The global UV stabilizer market size, in terms of value, is projected to reach USD 324.4 Million by 2020, registering a CAGR of 6.7% between 2015 and 2020. The growing manufacturing industries, increasing demand for UV stabilizers in the Asia-Pacific region, increasing demand of wood coatings in North America, and continuous product development, expansion, and merger & acquisition activities under …
- Shigella Infections (Shigellosis)：グローバル臨床試験レビューH1, 2013Shigella Infections (Shigellosis) Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, “Shigella Infections (Shigellosis) Global Clinical Trials Review, H1, 2013" provides data on the Shigella Infections (Shigellosis) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Shigella Infections (Shigellosis). It i …
- 自動車ブレーキ摩擦材の世界市場2015-2019About Automotive Brake Friction Materials Friction materials are used to stop or control the motion of a solid surface by applying force to it. These are widely used in the automobile, industrial, and aerospace sectors to stop the motion of wheels. In the automotive sector, they are useful for enhancing a vehicle’s performance and efficiency. Frictional materials are added to brakes to change the …
- レシチン/リン脂質の世界市場動向及び予測The lecithin & phospholipids report analyzes the market, in terms of region, lecithin type, source, and application. The lecithin & phospholipids market is growing with increase in the demand for convenience foods and healthcare products. The lecithin and phospholipids market was valued at USD 784.5 million and USD 1.67 billion in 2014 and is projected to grow at a CAGR of 5.9% and 19.1% from 2015 …
- 静電容量式タッチセンサ（非ガラス表面用）の世界市場：プラスチック、ITOフィルム、サファイア、銀ナノワイヤー、グラフェン、メタルメッシュ等In 2012, with the introduction of the first touch-enabled smartphones, iPhone by Apple (U.S.) has triggered the capacitive sensors market immensely. No sooner after this launch, Samsung (South Korea) also entered into this competition by launching the Samsung S5 with the capacitive sensor technology. Rapid technological developments, increasing demand for simple and secured access for users to the …
- デジタルマーケティングのグローバル市場（2014-2018）About Digital Marketing Digital marketing uses various tools for digital marketing functions such as sales CRM, marketing automation, e-commerce, e-mail, WCM, web analytics, and social CRM. All these software tools collectively help an organization to develop and implement effective marketing strategies. These tools are developed to serve specific functions in the Global Digital Marketing market a …
